ADVENT On Air

By ADVENT Program

The latest updates in type 2 inflammatory science, brought to you by leading experts in the field.

The ADVENT On Air podcast will feature scientific conversations that explore new research into the pa... more

4.7

1313 ratings

Download on the App Store

Download on the App Store

Get it on Google Play

FAQs about ADVENT On Air:

How many episodes does ADVENT On Air have?

The podcast currently has 15 episodes available.

ADVENT On Air episodes:

August 26, 2024Breathing Easy: Navigating Lung Function in Pediatric Severe Asthma With Spirometry and Beyond
Join Drs. Wanda Phipatanakul and Theresa Guilbert as they discuss the importance of routine lung function assessment in pediatric asthma patients.

ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.

This podcast is intended for healthcare professionals only.

Disclaimer:
This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.
The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program
The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits
Speaker disclosures:
Theresa Guilbert, MD, reports grants from GSK, grants from NIH, grants and consult fees from Sanofi/Regeneron/Amgen, grants and consult fees from AstraZeneca, consult fees from Genentech, consult fees from Polarean, grants and consult fees from OM Pharma, consult fees from AiCME, consult fees from Best Pharmaceuticals for Children Act (BPCA), consult fees from PlatformQ health, royalties from UpToDate.
Wanda Phipatanakul MD, MS, consults for Genentech, Novartis, Sanofi, Regeneron, GSK, AstraZeneca.

© 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.
MAT-GLB-2401186 - 1.0 - 08/2024
MAT-US-2408147 v1.0 - P Exp Date: 08/14/2026
...more
23min
August 15, 2024Exploring PN as a Distinct and Unique Disease
Dr. Sonja Ständer and Dr. Shawn Kwatra discuss the unique characteristics of prurigo nodularis (PN) and its clinical definition and explore how some of these characteristics are shared with atopic dermatitis, including underlying type 2 inflammation. They also discuss the need to raise awareness of this disease among both physicians and patients and educate that this is not a psychodermatological disorder.

ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.

This podcast is intended for healthcare professionals only.

Disclaimer:
This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.
The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program
The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits
Speaker disclosures:
Dr. Shawn Kwatra is an advisory board member/consultant for Abbvie, Amgen, Arcutis Biotherapeutics, Aslan Pharmaceuticals, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Dermavant, Galderma, Incyte Corporation, Johnson & Johnson, Leo Pharma, Novartis Pharmaceuticals Corporation, Pfizer, Regeneron Pharmaceuticals, and Sanofi and has served as an investigator for Galderma, Incyte, Pfizer, and Sanofi.
Dr. Sonja Ständer was speaker and/or consultant and/or Investigator and/or has received research funding from AbbVie, Almirall, Beiersdorf, BMS, Clexio, Eli Lilly, FomF, Galderma, German Research Foundation (DFG), Integrity CE, Kiniksa, Leo Pharma, L’Oréal, MEDahead, Moroscience, NACCME, Novartis, Omnicuris, P.G. Unna Academy, Pfizer, Sanofi, TouchIME, UCB, Vifor, and WebMD.

© 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.
MAT-GLB-2400085- 1.0 - 08/2024
MAT-US-2408113 v1.0-P Expiration Date: 08/13/2026
...more
31min
August 08, 2024Charting a New Course: The Frontier of Early Intervention and Disease Modification in AD
Join Drs. April Armstrong and Lisa Beck for a conversation around the long-term burden and effects of AD. They will discuss the underlying pathophysiology of AD and how early intervention and disease modification may impact disease course.

ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.

This podcast is intended for healthcare professionals only.

Disclaimer:
This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.
The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program
The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits
Speaker disclosures:
April Armstrong, MD, MPH has served as a research investigator, scientific advisor, or speaker to AbbVie, Amgen, Almirall, Arcutis, ASLAN, Beiersdorf, BI, BMS, EPI, Incyte, Leo, UCB, Janssen, Lilly, Mindera, Nimbus, Novartis, Ortho, Sun, Dermavant, Dermira, Sanofi, Takeda, Organon, Regeneron, Pfizer and Ventyx
Lisa Beck MD, consults for Abbvie, Allakos, Arcutis Biotherapeutics, Arena Pharmaceuticals, Aslan Pharma, Astria Therapeutics, Celldex, Dermavent, DermTech, Escient Pharma, Eli Lilly Company, Evelo Biosciences, Galderma, Incyte, Janssen, LEO Pharma, Merck, Nektar Therapeutics, Numab Therapeutics, Pfizer, Proteologix, Rapt Therapeutics, Regeneron, Ribon Therapeutics, Sanofi/Genzyme, Sanofi-Aventis, Sitryx Therapeutics, Stealth BioTherapeutics, Trevi Therapeutics, Union Therapeutics, Xencor and Yuhan and has been an Investigator for Abbvie, Astra-Zeneca, DermTech, Kiniksa, Pfizer, Regeneron, Ribon Therapeutics and Sanofi.

© 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.
MAT-GLB-2401395 - 1.0 - 07/2024
MAT-US-2407636 v1.0 - P Exp Date: 07/31/2026
...more
24min
June 06, 2024First-hand Experience: Practical Insights on the Diagnosis and Assessment of Atopic Dermatitis of the Hands and Feet
Dr Linda Stein Gold and Dr Jonathan Silverberg discuss the challenges associated with diagnosis of atopic dermatitis of the hands and feet and how disease severity can be assessed in clinical practice.
ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.
This podcast is intended for healthcare professionals only.

Disclaimer:
This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.
The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program
The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits
Speaker disclosures:
Dr Jonathan Silverberg: Honoraria as a consultant and/or advisory board member for AbbVie, Alamar, Aldena Therapeutics, Amgen, AOBiome, Apollo Pharma, Arcutis, Arena Pharmaceuticals, Asana, ASLAN Pharmaceuticals, Attovia, BiomX, Biosion, Bodewell, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Celgene, Connect Biopharma, CorEvitas, Dermavant, FIDE, Galderma, GSK, Incyte, Invea, Kiniksa, LEO Pharma, Lilly, Merck, MyOr Diagnostics, Nektar, Novartis, Optum, Pfizer, RAPT Therapeutics, Recludix, Regeneron, Sandoz, Sanofi-Genzyme, Shaperon, Target RWE, Teva, UNION, and UpToDate. Speaker for AbbVie, LEO Pharma, Lilly, Pfizer, Regeneron, and Sanofi-Genzyme. Institution received grants from Galderma, Incyte, and Pfizer.
Dr Linda Stein Gold: Investigator/advisor and/or speaker for AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Dermavant, Incyte, LEO Pharma, Pfizer, Regeneron, and Sanofi.

© 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.
MAT-GLB-2402602- 1.0 - 05/2024
MAT-US-2405594 v1.0 - P Exp Date: 06/04/2026
...more
11min
June 06, 2024Getting to Grips with Atopic Hand and Foot Dermatitis: What Is It, and What Does It Mean for Patients?
Dr Linda Stein Gold and Dr Jonathan Silverberg discuss the epidemiology, clinical presentation, and classification of atopic dermatitis of the hand and feet as well the as quantifying the multidimensional burden it has on patients' quality of life in clinical practice.
ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.
This podcast is intended for healthcare professionals only.

Disclaimer:
This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.
The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program
The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits
Speaker disclosures:
Dr Jonathan Silverberg: Honoraria as a consultant and/or advisory board member for AbbVie, Alamar, Aldena Therapeutics, Amgen, AOBiome, Apollo Pharma, Arcutis, Arena Pharmaceuticals, Asana, ASLAN Pharmaceuticals, Attovia, BiomX, Biosion, Bodewell, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Celgene, Connect Biopharma, CorEvitas, Dermavant, FIDE, Galderma, GSK, Incyte, Invea, Kiniksa, LEO Pharma, Lilly, Merck, MyOr Diagnostics, Nektar, Novartis, Optum, Pfizer, RAPT Therapeutics, Recludix, Regeneron, Sandoz, Sanofi-Genzyme, Shaperon, Target RWE, Teva, UNION, and UpToDate. Speaker for AbbVie, LEO Pharma, Lilly, Pfizer, Regeneron, and Sanofi-Genzyme. Institution received grants from Galderma, Incyte, and Pfizer.
Dr Linda Stein Gold: Investigator/advisor and/or speaker for AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Dermavant, Incyte, LEO Pharma, Pfizer, Regeneron, and Sanofi.

© 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.
MAT-GLB-2400314 - 1.0 - 06/2024
MAT-US-2405589 v1.0 - P Exp Date: 06/04/2026
...more
18min
May 21, 2024More Than Just Difficulty Swallowing: Disease Burden and Diagnosis of EoE
Dr. Joshua Wechsler and Prof. Arjan Bredenoord discuss the burden of disease in patients with EoE, the impact on quality of life, and how to overcome challenges in identifying EoE.

ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.
This podcast is intended for healthcare professionals only.

Disclaimer:
This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.
The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program
The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits
Speaker disclosures:
Arjan Bredenoord, MD, PhD (Adult Gastroenterologist): Professor, Gastroenterology and Hepatology, Amsterdam University Medical Center, Amsterdam, the Netherlands
Joshua Wechsler, MD, MSci (Pediatric Gastroenterologist): Attending Physician, Division of Gastroenterology, Hepatology & Nutrition; Campaign Urging Research for Eosinophilic Disorders (CURED) Foundation Research Scholar; Medical Director, Eosinophilic Gastrointestinal Disorders Program; Assistant Professor in Pediatrics & Medicine, Northwestern University – The Feinberg School of Medicine

© 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.
MAT-GLB-2304791 - 1.0 - 05/2024
MAT-US-2404998 v1.0 - P Expiration Date: 05/15/2026
...more
13min
March 29, 2024Remission in CRSwNP
Professor Peter Hellings and Dr. Stella Lee discuss the concept of remission for patients with chronic rhinosinusitis with nasal polyps.

ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.
This podcast is intended for healthcare professionals only.

Disclaimer:
This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.
The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program.
The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits.
Speaker disclosures:
Professor Peter Hellings has received clinical trial funding and/or advisory board fees from Sanofi, Novartis, GlaxoSmithKline, Stallergenes, ALK, Viatris/Mylan.
Doctor Stella Lee has received clinical trial funding and/or advisory board fees from AstraZeneca, Genentech, GlaxoSmithKline, Lyra Therapeutics, OptiNose, Sanofi and Regeneron.

© 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.
MAT-GLB-2400409 v1.0 03/2024
MAT-US-2402818 v1.0 - P Expiration Date: 03/12/2026
...more
20min
March 22, 2024Dysphagia in EoE: How Can You See Beyond Patients’ Adaptive Behaviors?
Dr. Ikuo Hirano and Dr. Margaret (Peggy) Marcon highlight why dysphagia may be overlooked and share insights from their own clinical practice on how to unmask EoE behind patients' adaptive behaviors.

ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.
This podcast is intended for healthcare professionals only.

Disclaimer:
This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.
The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program
The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits
Speaker disclosures:
Dr. Ikuo Hirano, MD has received consultation fees from Adare/Ellodi, Allakos, Pfizer/Arena, AstraZeneca, Celgene/Receptos, Eli Lilly, EsoCap, Gossamer Bio, Parexel/Calypso, Regeneron, Sanofi, Shire/Takeda, Phathom, Nexstone. He has participated in clinical trials for AstraZeneca, Celgene/BMS, Regeneron, Shire/Takeda, Ellodi/Adare, Allakos and been a member of Speaker Bureaus for Sanofi and Regeneron.
Dr. Peggy Marcon has received fees from Nutricia, Sanofi for education.

© 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.
MAT-GLB-2304790 v1.0 03/2024
MAT-US-2402674 v1.0 - P Expiration Date: 03/07/2026
...more
17min
March 07, 2024The Road Ahead: Achieving Remission for Patients with Asthma
Join renowned pulmonologists Klaus Rabe, MD, PhD, FERS, and Ian Pavord, DM, FRCP, FERS, as they discuss on-treatment clinical remission as a goal in asthma management beyond disease control, and highlight the role of type 2 inflammatory biomarkers in optimizing patient outcomes.

ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.
This podcast is intended for healthcare professionals only.

Disclaimer:
This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.
The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program.
The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits.
Speaker disclosures:
Ian D. Pavord, MA, DM, FRCP, FERS, FMedSci has received honoraria for speaking at sponsored meetings from Astra Zeneca, Boehringer Inglehiem, Aerocrine, Almirall, Novartis, Teva, Chiesi, Sanofi/Regeneron, Menarini and GSK and payments for organising educational events from AZ, GSK, Sanofi/Regeneron and Teva. He has received honoraria for attending advisory panels with Genentech, Sanofi/Regeneron, Astra Zeneca, Boehringer Ingelheim, GSK, Novartis, Teva, Merck, Circassia, Chiesi and Knopp and payments to support FDA approval meetings from GSK. He has received sponsorship to attend international scientific meetings from Boehringer Ingelheim, GSK, Astra Zeneca, Teva and Chiesi. He has received a grant from Chiesi to support a phase 2 clinical trial in Oxford. He is co-patent holder of the rights to the Leicester Cough Questionnaire and has received payments for its use in clinical trials from Merck, Bayer and Insmed. In 2014-5 he was an expert witness for a patent dispute involving Astra Zeneca and Teva.
Klaus Rabe, MD, PhD has served on FDA and EMA panels for registration of drug for COPD. He has served on advisory panels for AstraZeneca, Boehringer Ingelheim, Chiesi Pharmaceuticals, Sanofi & Regeneron, Berlin Chemie, Novartis, GlaxoSmithKline, Insmed, CSL Behring making asthma and COPD drugs, and participated in clinical trials. He has never worked with the tobacco industry (and never will). He has no shares or proprietary interests of any kind.

© 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.
MAT-GLB-2303834 V1 02/2024
MAT-US-2402193 v1.0 - P Expiration Date: 02/26/2026
...more
16min
January 19, 2024Exploring Loss of Smell in CRSwNP: Clinical Relevance and Patient Impact
Professors Wytske Fokkens and Joaquim Mullol discuss the burden of smell loss and the emerging science on how inflammation drives olfactory dysfunction in patients with CRSwNP.
ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.
This podcast is intended for healthcare professionals only.
Disclaimer:
This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.
The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program
The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits
Speaker disclosures:
Professor Wytske Fokkens, MD, PhD has received consultation/speaker fees from Novartis, Sanofi, GSK and Dianosic.
Professor Joaquim Mullol, MD, PhD reports have received research grants, participated in clinical trials, been a member of Speaking Bureaus and Advisory Boards from Allakos, AstraZeneca, Glenmark, GSK, Menarini, MSD, Mitsubishi-Tanabe, Noucour/Uriach Group, Novartis, Optinose, Proctor & Gamble, Sanofi-Genzyme, Regeneron Pharmaceuticals, Viatris.

© 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.
MAT-GLB-2400013 v1.0 01/2024
MAT-US-24000221 v1.0 - P Expiration Date: 01/08/2026
...more
18min

FAQs about ADVENT On Air:

How many episodes does ADVENT On Air have?

The podcast currently has 15 episodes available.